|Bid||43.85 x 900|
|Ask||46.55 x 900|
|Day's Range||45.70 - 46.08|
|52 Week Range||40.38 - 51.18|
|Beta (5Y Monthly)||0.38|
|PE Ratio (TTM)||30.01|
|Earnings Date||Apr 24, 2023 - Apr 28, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.90|
International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the fourth QIAGEN instrument to receive Red Dot award, highlights strategy of upgrading portfolio to add new features – in particular wireless connectivity // QIAxcel Connect offers scientists many benefits for nucleic acid analysis with minimal handling time, flexible throughput and speedVenlo, the Netherlands, March 29, 2023 (GLOBE NEWSWIRE) -- QIAGEN today announced tha
Key Insights Significantly high institutional ownership implies Qiagen's stock price is sensitive to their trading...
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 8.33% and 2.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?